809 related articles for article (PubMed ID: 18703937)
1. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
3. Assessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction Questionnaire.
Wyrwich K; Harnam N; Revicki DA; Locklear JC; Svedsäter H; Endicott J
Int Clin Psychopharmacol; 2009 Nov; 24(6):289-95. PubMed ID: 19707153
[TBL] [Abstract][Full Text] [Related]
4. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
Pollack MH; Endicott J; Liebowitz M; Russell J; Detke M; Spann M; Ball S; Swindle R
J Psychiatr Res; 2008 Oct; 42(12):1042-9. PubMed ID: 18221755
[TBL] [Abstract][Full Text] [Related]
5. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
6. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Bech P; Lönn SL; Overø KF
J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
[TBL] [Abstract][Full Text] [Related]
7. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
Sheehan DV; Harnett-Sheehan K; Spann ME; Thompson HF; Prakash A
Int Clin Psychopharmacol; 2011 Mar; 26(2):75-83. PubMed ID: 21102344
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
9. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.
Endicott J; Paulsson B; Gustafsson U; Schiöler H; Hassan M
J Affect Disord; 2008 Dec; 111(2-3):306-19. PubMed ID: 18774180
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Allgulander C; Jørgensen T; Wade A; François C; Despiegel N; Auquier P; Toumi M
Curr Med Res Opin; 2007 Oct; 23(10):2543-9. PubMed ID: 17825130
[TBL] [Abstract][Full Text] [Related]
12. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Bose A; Korotzer A; Gommoll C; Li D
Depress Anxiety; 2008; 25(10):854-61. PubMed ID: 18050245
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
14. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Baldwin DS; Stein DJ; Dolberg OT; Bandelow B
Hum Psychopharmacol; 2009 Jun; 24(4):269-75. PubMed ID: 19334042
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
16. Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial.
Muller JE; Wentzel I; Koen L; Niehaus DJ; Seedat S; Stein DJ
Int Clin Psychopharmacol; 2008 Jan; 23(1):43-8. PubMed ID: 18090507
[TBL] [Abstract][Full Text] [Related]
17. Patient-rated troubling symptoms of depression instrument results correlate with traditional clinician- and patient-rated measures: a secondary analysis of a randomized, double-blind, placebo-controlled trial.
Pandina GJ; Revicki DA; Kleinman L; Turkoz I; Wu JH; Kujawa MJ; Mahmoud R; Gharabawi GM
J Affect Disord; 2009 Nov; 118(1-3):139-46. PubMed ID: 19321206
[TBL] [Abstract][Full Text] [Related]
18. The effect of escitalopram on sleep problems in depressed patients.
Lader M; Andersen HF; Baekdal T
Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
Russell JM; Weisberg R; Fava M; Hartford JT; Erickson JS; D'Souza DN
Depress Anxiety; 2008; 25(7):E1-11. PubMed ID: 17587217
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
